Company is an integrated contract development and manufacturing organization supporting the international pharmaceutical and biotechnology industries and has added an Xcelodose^® 600S system to its product development capabilities in response to client requirements for preclinical and early phase clinical GMP supply. For simple formulations of API or powder-in-capsule, the system can significantly decrease processing time and API usage res ulting in cost savings when compared to hand filling options. The included Xcelohood™ system offers containment when filling capsules with API of high or unknown toxicity. The company is installing the Xcelodose^® system in its state-of-the-art product development facility in Craigavon, UK.